Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Comment by pabalooon Mar 02, 2021 1:04pm
105 Views
Post# 32695920

RE:RE:RE:RE:Debt-Free CPH: At 1.5 times its 2020 EBITDA And The Buyback

RE:RE:RE:RE:Debt-Free CPH: At 1.5 times its 2020 EBITDA And The BuybackTrulance was a huge coo for the company negotiating around Bausch to steal the Canadian rights from a now defunct Synergy Pharma. Bausch then bought out the bankrupt company without the Canadian rights. Along came the new management team at Cipher and somehow bungled up the contract and subsequent lawsuit costing them there entire investment plus cost to be determined at a later date. This alone will cost them there profits for the entire year last year. Add to this there number 1 drug absorica will soon be the LD version owned by Sun Pharma and you can see that starting December revenue will fall off a cliff with only the Canadian version Eupuris to prop up dwindling revenue. What a complete debacle by a bunch of clowns. Just my opinion. Blindsided me when Swapper saw it before me!
<< Previous
Bullboard Posts
Next >>